首页> 外文期刊>Clinics in laboratory medicine >Inflammatory and long-term risk markers.
【24h】

Inflammatory and long-term risk markers.

机译:炎症和长期危险指标。

获取原文
获取原文并翻译 | 示例
           

摘要

Evidence indicates that the process of atherosclerosis has an inflammatory component. Markers of inflammation have been explored as a means for assessing (predicting) risk for the disease. Studies that evaluated the usefulness of fibrinogen, highly sensitive C-reactive protein, interleukin-6, myeloperoxidase, and soluble CD40 ligand for risk prediction are reviewed. Criteria for identifying a clinically useful test are discussed, along with the use of relative risk as a means for making clinically useful comparisons. It is concluded that clinically useful markers for routine screening and risk stratification have not been established, that prospective studies will be necessary to confirm the usefulness of current markers, and that on the basis of current knowledge, it will be a challenge to show that any of those inflammatory markers discussed herein will meet the needed criteria. Continued research into basic mechanisms by which inflammation acts in atherosclerosis may be necessary to identify useful markers for prediction.
机译:有证据表明,动脉粥样硬化的过程具有炎症成分。炎症标记已被探索为评估(预测)疾病风险的一种手段。综述了评估纤维蛋白原,高敏C反应蛋白,白介素6,髓过氧化物酶和可溶性CD40配体对风险预测的实用性的研究。讨论了鉴定临床有用测试的标准,以及使用相对风险作为进行临床有用比较的一种手段。结论是,尚未建立用于常规筛查和风险分层的临床有用的标记物,有必要进行前瞻性研究以确认当前标记物的有效性,并且基于现有知识,证明任何本文讨论的那些炎症标志物中的一部分将满足所需标准。可能需要继续研究炎症在动脉粥样硬化中起作用的基本机制,以鉴定有用的预测标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号